Genedrive (LSE:GDR), the Manchester-based point-of-care molecular diagnostics company, has spent 2026 rebuilding its funding base while pressing ahead with efforts to embed its rapid genetic tests in the NHS and overseas. In a trading update published in July 2026, the company flagged that full-year income was expected to roughly double, and it has since attracted attention for a pharmacogenetic testing agreement with Thermo Fisher Scientific. With its financial year having ended in June, investors are now awaiting fuller detail on its performance and outlook.

What the Company Does

Genedrive develops rapid genetic tests designed to be run near the patient rather than in a central laboratory. Its best-known product, the MT-RNR1 ID Kit, identifies newborns carrying a genetic variant that makes them vulnerable to hearing loss if treated with certain antibiotics, allowing clinicians to choose alternative treatments quickly. Its CYP2C19 ID Kit is aimed at stroke care, helping identify patients who may not respond well to the commonly used drug clopidogrel. Both fit within the broader field of pharmacogenetics, where genetic information guides prescribing decisions.

Latest Developments

Earlier in 2026, Genedrive proposed a share raise of up to £6.0 million and, separately, a direct subscription to raise up to £3.5 million. It published a circular and notice of general meeting to approve the fundraising, and later announced the result of that meeting. Prior announcements had related to a Shareholder loan. The company has also reported a board change and a director/PDMR notification.

In April 2026, Genedrive announced a consultation to inform NHS England's commercial strategy for rapid MT-RNR1 testing, a step towards wider adoption of the test across neonatal units. More recently, the shares rose 8% on news of a pharmacogenetic testing deal with Thermo Fisher. In a separate interview, chief executive commentary highlighted NHS adoption and international expansion as key drivers of the company's point-of-care testing strategy.

Financial Picture

According to its July 2026 trading update, Genedrive expected income for the financial year to June 2026 to approximately double, with solid Revenue growth and expanded market reach. Precise figures were not available at the time of writing. The company has historically been loss-making as it invests in commercialisation, which explains its reliance on share fundraising and shareholder loans. No Dividend is paid.

Sector and index Context

Genedrive is a constituent of the FTSE AIM All Share Index, which includes a number of small healthcare and diagnostics businesses. Pharmacogenetic testing is gaining recognition as health systems look for ways to make prescribing safer and more effective, and the NHS has shown interest in rapid genomic tools. However, adoption in publicly funded health systems can be slow, as procurement, clinical guidance and budget decisions must align before tests are rolled out widely.

Key Risks

Key risks include the pace of NHS procurement and reimbursement decisions, which can affect the timing of revenue. The company has needed repeated funding, and further raises could dilute existing shareholders. Competition from other genetic testing approaches, regulatory requirements in new markets and the execution of commercial partnerships also present uncertainty. As a small AIM stock, Genedrive's shares can move sharply on news.

What to Watch Next

Investors will look to the company's full-year results for the period to June 2026 for confirmation of the revenue growth flagged in July, as well as details of cash reserves and costs. Progress on the NHS England commercial strategy for MT-RNR1 testing, the commercial impact of the Thermo Fisher agreement and further international distribution deals are likely to be key indicators of momentum.